Board of directors



Anders Lundberg

Chairman of the Board (member of the board since 2017)

About: M.Sc. Mechanical Engineering, KTH, Stockholm, Sweden. Founder and CEO of a telecom equipment supplier recognized by the market and later brought to a successful IPO in 2011 on the MID-CAP list OMX-Nasdaq [TRMO:Transmode]

Other assignments: Member of the board of AJ Lundberg Kapitalförvaltning AB and Modern Car Group International AB. Deputy member of the board of Sollentunahem AB, Sollentunafastigheter 1 AB, Sollentunafastigheter 2 AB and Sollentunafastigheter 3 AB.

Holdings in the Company: Via AJ Lundberg Kapitalförvaltning AB 289109 shares, 67259 warrants T0 1 and 0 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Dr. Michael Häggman

Board Member since 2018

About: M.D, Ph.D. associate professor, department of Urology, Akademiska University Hospital, Uppsala, Sweden. More than 30 years of experience practicing as urologist with an extensive national and international network among urologists.

Other assignments: General partner in Skrotum Kommanditbolag and deputy member of the board of Kardinaltalet AB.

Holdings in the Company: 14817 shares, 5767 warrants T0 1 and 0 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Karlheinz Schmelig

Board Member since 2013

About: BSc in Business Administration, DHBW Mannheim, Germany. MBA, Kelley School of Business, Bloomington, USA.Co-Founder and General Managing partner, Creathor Venture Management GmbH, Germany.

Other assignments: Senior Advisor to German Ministry of Research and Development, member of the Issuer Markets Advisory Committee of Deutsche Börse and former member of the Invest Europe Venture Council. Experienced in all aspects of scaling companies into global technology and industry leaders across various healthcare subsectors.

Holdings in the Company: Via Creathor Ventures 3079911 shares, 443561 warrants T0 1 and 0 warrants 2020/2023B

Dependent in relation to Prostatype Genomics, its senior management and major shareholders.

Håkan Englund

Board Member since 2019

About: Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden. CEO and owner, JDS Invest. More than 30 years of operational and investment experience from life science and health care industry with focus on commercialization and business development. Håkan has held several leading management positions at Pharmacia Biotech and Phadia and has during his career developed extensive national and international relevant networks.

Other assignments: Chairman of the Board, SecureAppBox, member of the board, Immuneed, member of the board Antrad Medical, deputy board director Ultimovax (Norway), member of the board GlycoBond. Board member Stockholm/Uppsala Chamber of Commerce.

Holdings in the Company: Via JDS Invest AB 707605 shares, 276655 warrants T0 1 and 0 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Dr. Christoph Petry

Board Member since 2019

About: Doctoral Thesis, Max-Planck Institute for Medical Research, Heidelberg, Germany. M.Sc in Chemistry, University of Erlangen, Germany. Previously founder, Managing Director and CEO of Sividon Diagnostics and Head of Siemens Healthcare Diagnostics, Molecular Research Germany as well as 10 years of experience from various management positions at Bayer.

Other assignments: Managing Director m2p-labs GmbH I Microbioreactors, Germany

Holdings in the Company: 0 shares, 0 warrants T0 1 and 41856 warrants 2020/2023B

Independent in relation to Prostatype Genomics, its senior management and major shareholders.